Brain Cancer Diagnostics Market: as the WHO 2021 CNS Classification makes molecular testing mandatory rather than optional for glioma diagnosis, tissue biopsy workflows are shifting from histopathology-only review to combined imaging and molecular workup, so NGS panel volume is compounding alongside every MRI-detected lesion, and portable, helium-light imaging platforms are widening diagnostic access beyond tertiary neuro-oncology centres.

The global brain cancer diagnostics market size was USD 2.14 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period.Market revenue growth is driven by factors such as the WHO 2021 CNS Classification's mandatory molecular testing requirement, sustained institutional investment in AI-enabled MRI and imaging platforms, and the rising global incidence of primary brain and central nervous system tumours.The first driving factor is the WHO 2021 Classification of Tumours of the Central Nervous System, which made IDH mutation status, 1p/19q co-deletion, and MGMT promoter methylation mandatory molecular parameters for glioma diagnosis rather than optional supplements to histopathology.This regulatory-equivalent classification standard now requires an NGS panel or targeted molecular test alongside nearly every primary brain tumour tissue biopsy processed at an NCI-designated cancer centre.The second driving factor is sustained institutional investment in AI-enabled MRI and advanced imaging platforms at academic neurosurgical centres.GE HealthCare reported total FY2024 revenue of USD 19.7 Billion, with an Imaging segment of approximately USD 8.9 Billion spanning the CT, MRI, and molecular imaging platforms used in neuro-oncology diagnosis.The third driving factor is the rising global incidence of primary brain and central nervous system tumours.The Central Brain Tumor Registry of the United States documented 489,718 incident primary brain and CNS tumours over the 2017 to 2021 period, establishing a sustained diagnostic imaging and biopsy workload.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single WHO 2021-compliant molecular panel widens its addressable revenue every time a health system adds a new mandatory parameter to its glioma workup, without the laboratory having to win a new referral relationship from zero.Once a neuro-oncology pathology laboratory adopts an NGS panel for IDH and MGMT testing, each additional mandatory parameter such as 1p/19q co-deletion or TERT promoter status adds incremental test volume on the same sample and the same laboratory relationship, so panel revenue compounds as the WHO framework's parameter list grows rather than requiring a new biopsy pathway.As a result, demand and revenue share are concentrating around comprehensive genomic profiling panels that cover the full WHO 2021 parameter set in a single tissue pass, that hold the broadest mandatory-marker coverage, and the forecast tilts toward these all-in-one panels rather than single-marker PCR tests ordered separately.For instance, in January 2026, Illumina, United States, secured Centers for Medicare and Medicaid Services reimbursement for its TruSight Oncology Comprehensive panel at USD 2,989.55 per test under a dedicated Proprietary Laboratory Analysis code, widening the payer-covered addressable base for the same panel without a new companion diagnostic submission for each cancer type it already covers.These are some of the key factors driving revenue growth of the market.

Because 3-Tesla MRI systems cost USD 1.5 Million to USD 3 Million per installation and 7-Tesla systems exceed USD 7 Million, advanced neurological imaging access remains concentrated at tertiary academic medical centres, so community oncology practices in lower-income regions continue to rely on older 1.5T MRI or CT platforms with reduced tumour characterisation capability.

Liquid biopsy reimbursement is a second constraint, because most national payers require additional clinical utility evidence before covering blood-based ctDNA brain tumour testing alongside mandatory tissue biopsy, and laboratories offering both pathways therefore see slower revenue conversion on the liquid biopsy service line.

Regional incidence and reimbursement mismatch is a third constraint, since the highest brain and CNS cancer incidence rates are concentrated in Northern America and Western Europe, so markets with lower incidence but weaker reimbursement infrastructure see imaging and molecular diagnostic adoption lag structural demand.

These factors substantially limit brain cancer diagnostics market growth over the forecast period.

The clearest driver of demand is the WHO 2021 Classification of Tumours of the Central Nervous System, which made IDH mutation status, 1p/19q co-deletion, and MGMT promoter methylation mandatory molecular parameters for glioma classification. A molecular classification standard only changes purchasing behaviour if payers and pathology accreditation bodies treat it as a compliance requirement rather than a research option, and WHO 2021 has been adopted as exactly that standard by neuro-oncology pathology programmes worldwide, so every new glioma diagnosis now requires a molecular test order alongside the tissue biopsy. More than 60% of newly diagnosed glioma cases at NCI-designated cancer centres now receive a comprehensive genomic profiling panel rather than single-marker PCR testing alone. The recent record shows the pace. In January 2026, Illumina, United States, secured CMS reimbursement for its TruSight Oncology Comprehensive panel, and in June 2025 Hyperfine, United States, received FDA clearance for its next-generation Swoop portable MRI system with Optive AI software, extending brain imaging access to neurology offices beyond tertiary neurosurgical centres. The effect on the market is that molecular diagnostic panel revenue is compounding on top of, rather than instead of, existing imaging revenue at every glioma diagnostic pathway. These are some of the key factors driving revenue growth of the market.

The second driver is the introduction of helium-light and portable MRI platforms that reduce the infrastructure barrier to advanced brain imaging. Advanced MRI systems have historically required large, dedicated helium-cooled installations that only tertiary academic medical centres can afford and maintain, and vendors are now engineering around that constraint, so imaging capability is spreading into settings that previously relied on CT or older 1.5T platforms. GE HealthCare's Freelium platform uses less than 1% of the helium of a conventional MRI system, and Siemens Healthineers has now cleared three distinct helium-reduced or helium-free MRI platforms with the FDA. In December 2025, Siemens Healthineers, Germany, received FDA clearance for its Magnetom Terra.X 7T MRI system, and in November 2025 GE HealthCare, United States, entered an agreement to acquire Intelerad Medical Systems for USD 2.3 Billion, adding cloud-enabled enterprise imaging informatics to its neuro-oncology imaging portfolio. The effect on the market is that imaging capacity for brain tumour detection is expanding into community hospitals and neurology offices that previously referred patients out for advanced MRI. These are some of the key factors driving revenue growth of the market.

“Hyperfine's Swoop system extends FDA-cleared brain MRI into the neurology office setting, a site of care that had no advanced imaging access at all before 2025.”

The third driver is the rising global incidence of primary brain and central nervous system tumours documented by cancer registries. Diagnostic demand only grows sustainably if the underlying disease incidence is rising rather than plateauing, and CBTRUS and GLOBOCAN data both confirm brain and CNS cancer incidence is increasing across most world regions, so imaging and biopsy volume growth reflects genuine caseload growth rather than a one-time screening expansion. The Central Brain Tumor Registry of the United States documented 489,718 incident primary brain and CNS tumours over the 2017 to 2021 five-year period, with malignant tumours accounting for 128,865 cases. In 2025, academic cancer centres across North America and Western Europe, the two regions with the highest documented brain and CNS cancer incidence rates, continued expanding neuro-oncology tumour board capacity to manage rising referral volume. The effect on the market is that diagnostic imaging and molecular testing volume growth is outpacing general oncology diagnostic volume growth in the regions with the most developed reimbursement infrastructure. These are some of the key factors driving revenue growth of the market.

However, the brain cancer diagnostics market faces severe adoption constraints from advanced imaging capital cost and liquid biopsy reimbursement gaps.

Because 3-Tesla MRI systems are priced between USD 1.5 Million and USD 3 Million per installation and 7-Tesla systems exceed USD 7 Million, advanced neurological imaging access remains concentrated at tertiary academic medical centres in high-income countries, so community oncology practices and secondary hospitals in low- and middle-income countries continue to rely on older 1.5T MRI or CT platforms with materially reduced tumour characterisation capability.

Liquid biopsy reimbursement is a second constraint, because most national health systems require additional prospective clinical outcome data before covering blood-based ctDNA brain tumour genomic testing alongside mandatory tissue biopsy under the WHO 2021 framework, and laboratories offering ctDNA testing therefore see slower reimbursement conversion than for tissue-based panels.

Geographic incidence and infrastructure mismatch is the third constraint, since East Asia has the highest absolute brain and CNS cancer incident case count of any region globally, so the region with the greatest structural diagnostic demand is also the region where delayed hospital imaging procurement, as both GE HealthCare and Siemens Healthineers reported in China during fiscal 2024, constrains near-term revenue capture below the underlying disease burden.

These factors substantially limit brain cancer diagnostics market growth over the forecast period.

Based on cancer type, the global brain cancer diagnostics market is segmented into gliomas, meningiomas, pituitary tumours, and other primary brain tumours. Gliomas account for the largest revenue share as the highest-acuity diagnostic group requiring the most comprehensive multi-modal workup. The CBTRUS 2024 statistical report confirms glioblastoma as the most common malignant primary brain tumour in the United States, anchoring the glioma segment as the largest revenue contributor. The meningioma segment accounts for the second-largest revenue share and is expected to register a rapid revenue growth rate, driven by increasing incidental detection on brain imaging and growing adoption of DNA methylation profiling for meningioma grading under the WHO 2021 framework.

Based on end-use, the global brain cancer diagnostics market is segmented into hospitals and neurosurgical centres, oncology treatment centres, and cancer research institutes. Hospitals and neurosurgical centres account for the largest revenue share through inpatient brain tumour MRI scanning and CT-guided stereotactic biopsy procedures. The highest brain and CNS cancer incidence rates in Northern America and Western Europe anchor hospital and neurosurgical centre diagnostic revenue in high-income regions where tertiary neuro-oncology programmes with 3T and 7T MRI access are concentrated. Cancer research institutes account for the fastest-growing end-use segment, driven by liquid biopsy ctDNA research programmes and AI-enabled imaging algorithm development projects such as those supporting Hyperfine's Swoop system and Neosoma's AI segmentation tools.

Based on regional analysis, the brain cancer diagnostics market in North America accounted for the largest revenue share in 2025, at approximately 41% of global market revenue. The United States leads because it holds the CBTRUS-documented incidence of 128,865 malignant primary brain and CNS tumours over the 2017 to 2021 period and because it hosts the concentrated presence of NCI-designated comprehensive cancer centres equipped with 3T, 7T, and intraoperative MRI systems. GE HealthCare's Chicago headquarters and its November 2025 agreement to acquire Intelerad Medical Systems reinforce the region's imaging informatics leadership alongside Illumina's January 2026 CMS reimbursement win for its brain tumour-relevant genomic profiling panel. The concentration of FDA-cleared brain imaging and molecular diagnostic platforms in the United States also means new products and indications are often launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate in the global brain cancer diagnostics market over the forecast period.

Germany, France, and the United Kingdom represent the three largest national brain cancer diagnostics markets within Europe. Siemens Healthineers, headquartered in Erlangen, Germany, holds a leading European MRI market position through its Magnetom platform used extensively at German university hospital neuro-oncology departments, while European regulatory bodies require CE-IVD certification for molecular diagnostic panels used in WHO 2021-compliant glioma workup. The result is steady rather than rapid growth, shaped more by CE-IVD certification and national reimbursement timelines than by underlying diagnostic demand, which the GLOBOCAN data confirm is the highest of any world region in Western Europe.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global brain cancer diagnostics market over the forecast period.

China, Japan, and India represent the three largest national brain cancer diagnostics markets within the region. East Asia has the highest number of brain and CNS cancer incident cases of any world region, with China, India, and the United States as the top three countries by absolute incident case count, establishing the structural demand base for diagnostic imaging and molecular testing capacity expansion. The region's comparatively lower installed base of advanced MRI infrastructure leaves more room for growth than in the already-saturated North American and European markets.

The market in Latin America is expected to register a moderate revenue growth rate in the global brain cancer diagnostics market over the forecast period.

Brazil and Mexico represent the two largest national brain cancer diagnostics markets within the region, with federal university hospitals in São Paulo, Rio de Janeiro, and Mexico City operating 3T MRI platforms for brain tumour diagnostic imaging. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have raised freight and import costs for MRI contrast agent precursor chemicals and molecular diagnostic reagent components sourced through Middle Eastern trade routes, a disruption that has run through 2026 and slows procurement timelines for laboratories beyond the largest federal hospital networks in the region.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global brain cancer diagnostics market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for tertiary neuro-oncology imaging and molecular diagnostic capability, anchored by King Faisal Specialist Hospital and Research Center in Riyadh, while the wider Gulf and North African sub-regions are still building the basic 3T MRI infrastructure WHO 2021-compliant glioma classification requires from scratch.